Revvity to Divest China Immunodiagnostics Business
The divestiture removes a segment that accounted for approximately 6% of the company's total 2025 revenue.
Revvity, Inc. (RVTY) agreed to divest its immunodiagnostics business in China. The company did not disclose the financial terms or the identity of the buyer in the definitive agreement.
The transaction is expected to close by the end of 2027, subject to regulatory approvals and customary closing conditions.
Revvity entered into the agreement as part of a strategic decision to exit the specific business line in the region. The immunodiagnostics business in China represented approximately 6% of the company's total revenue for fiscal year 2025.
The company previously signaled this move in May 2026, when it announced its intention to divest the business and entered into a letter of intent with a prospective buyer.
Similar portfolio optimizations have occurred across the diagnostics and life sciences sector. Becton Dickinson (BDX) recently entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. Additionally, Lantheus Holdings (LNTH) agreed to sell its SPECT business to Illuminated Holdings to focus on its PET radiodiagnostics and microbubbles portfolio.